Abstract
Invasive respiratory interventions save infant lives yet, have negative consequences for their general health and neurodevelopment. Tools that can both accurately summarize the intensity of ventilation needed during an infant’s stay in the NICU and be used to make predictions about their future health and neurodevelopmental outcomes are currently lacking. Here we present the Prognostic Respiratory Intensity Scoring Metric (PRISM) as an accurate, summative tool of respiratory support needs in hospitalized neonates well suited for predicting an infant’s future neurodevelopmental outcomes. 218 infants were included in this study. We trained a classification and regression tree model using PRISM scores to classify respiratory diagnoses and compared performance to the Neonatal Sequential Organ Failure Assessment Respiratory subscore (nSOFA-r). PRISM outperforms the nSOFA-r in classifying infants with respiratory distress syndrome (PRISM AUC = 0.71, nSOFA-r AUC = 0.64) and chronic lung disease (PRISM AUC = 0.86, nSOFA-r AUC = 0.76) according to Delong’s Test (p=0.002, p=0.001). PRISM had significant associations both with an infant’s length of hospital stay (β = 0.03 (95% CI [0.02, 0.03], p < 0.001) and gestational age (β =−0.03 (95% CI [−0.03, −0.02], p <0.001). PRISM successfully identifies which infants will develop an intraventricular hemorrhage (83% accuracy) and is highly successful at determining which infants will develop retinopathy of prematurity (95% accuracy). PRISM is a tool designed for clinicians and researchers alike to summarize the invasive nature of neonatal respiratory support.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the National Institute of Mental Health (K01MH125173) and the Jefferson Trust at the University of Virginia.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of University of Virginia gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The only revision was the addition of one author, Dr. Santina Zanelli.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
